A once-daily pill has helped many people with vitiligo regain skin color, offering new hope for those living with the condition. Vitiligo causes white patches when the immune system attacks pigment-producing cells, and its visible effects can deeply affect self-esteem and mental health.
Because creams and light therapy can be slow, demanding, and hard to use on large areas, researchers are testing tablet treatments that work across the whole body. The new findings suggest that systemic therapy could become a practical option for patients with widespread or difficult-to-treat vitiligo.
How the vitiligo pill works
The drug, upadacitinib, belongs to a class of medicines called JAK inhibitors that dampen specific immune signals. By calming this overactive response, the treatment may reduce the immune attack on pigment cells and allow affected skin to gradually regain color.
JAK inhibitors are already used for several inflammatory and autoimmune diseases, including rheumatoid arthritis and eczema. Their potential in vitiligo has attracted growing interest, as the disorder is now widely recognized as an immune-driven condition rather than simply a cosmetic issue.
Details of the international trials
The new results come from two randomized, placebo-controlled phase 3 trials published in The Lancet and conducted at 138 centers in 18 countries. The studies enrolled 614 adults and adolescents aged 12 or older with non-segmental vitiligo affecting both the face and body.
Participants were randomly assigned to receive either 15 milligrams of upadacitinib or a placebo tablet once a day for 48 weeks. Neither the patients nor the investigators assessing their skin knew who was taking the active drug, helping to ensure objective comparisons.
What the researchers found
In the first trial, 25 percent of patients taking upadacitinib regained at least 75 percent of the color lost from their face, compared with 6 percent in the placebo group. The second trial produced similar findings, with 23 percent on the drug reaching this target versus 7 percent on placebo.
Improvements extended beyond facial areas. Across the two trials, 19 percent and 21 percent of treated patients regained at least half of the color lost from vitiligo-affected skin on the body, while only 6 percent of each placebo group experienced comparable gains.
Some people achieved particularly strong results. When the face alone was evaluated, 14 percent of those taking upadacitinib regained at least 90 percent of their lost pigment, compared with only 2 to 3 percent among placebo recipients. Skin repigmentation was still progressing when the 48-week treatment period ended.
Benefits and remaining limitations
Because the pill acts throughout the body, it may be especially useful for patients with extensive vitiligo or patches in areas that are hard to reach with creams. It could also reduce the need for frequent clinic visits, which are required for light-based therapies such as narrowband UVB.
However, most participants did not reach the main improvement targets. Roughly three in four did not achieve at least 75 percent facial repigmentation, and about four in five did not regain half of the color lost from vitiligo-affected skin overall, highlighting that the drug is not a cure for everyone.
Side effects and safety concerns
The trials recorded a range of adverse events. The most common problems among people taking upadacitinib included upper respiratory infections, acne, headaches, and inflammation of the nose and throat. Seven participants developed shingles during treatment.
Serious health issues occurred in 4 percent of treated patients in the first trial and 2 percent in the second, including severe infections and cardiovascular events. The 48-week follow-up was not long enough to fully understand rare or long-term risks, which are a concern for all JAK inhibitors.
Upadacitinib already carries warnings in other indications about potential risks of serious infections, malignancies, major cardiovascular events, and blood clots. Ongoing extension studies, lasting an additional 112 weeks, are tracking patients to clarify long-term safety and the durability of repigmentation.
Regulatory status and next questions
Based on these and related data, the European Union has approved upadacitinib for eligible adults and adolescents aged 12 and older with non-segmental vitiligo and facial involvement. Approval decisions in other regions, including the United States, remain under review or are evolving.
Key questions still need answers. It is unclear how long patients must stay on therapy, whether repigmented areas will retain their color after treatment stops, and which patients are most likely to respond. The trials also did not directly compare the pill with established options such as topical ruxolitinib or phototherapy.
Another limitation is that most participants were White, with people who have darker skin types underrepresented despite vitiligo’s high impact in these populations. Experts say more inclusive research will be needed to understand outcomes across diverse groups and to address global access and cost issues.
The studies were funded by AbbVie, the manufacturer of upadacitinib, which was involved in trial design, data analysis, and preparation of the published paper. Independent dermatologists note that while the results are encouraging, treatment decisions should weigh potential benefits against the known and emerging risks of systemic JAK inhibition.
For now, the findings offer cautious optimism that a once-daily pill could help some people with vitiligo recover meaningful amounts of skin color. As longer-term data accumulate, clinicians will gain a clearer picture of how this therapy fits alongside existing treatments in personalized care plans.
